This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Yeast and bacteria === Unlike humans, yeast and bacteria (except lactic acid bacteria, and E. coli in certain conditions) do not ferment glucose to lactate. Instead, they ferment it to ethanol and CO2. The overall reaction can be seen below:
During 1990, in the capital city of Mogadishu, the residents were prohibited from gathering publicly in groups greater than three or four. Fuel shortages, inflation, and currency devaluation impacted the economy. A thriving black market existed in the centre of the city as banks experienced shortages of local currency for exchange. Harsh exchange control regulations were introduced to prevent export of foreign currency. Although no travel restrictions were placed on foreigners, photographing many locations was banned. During daytime in Mogadishu, the appearance of any government military force was extremely rare. Alleged late-night operations by government authorities, however, included "disappearances" of individuals from their homes. In 1991, the Barre administration was ousted by a coalition of clan-based opposition groups, backed by Ethiopia's then-ruling Derg regime and Libya. Following a meeting of the Somali National Movement and northern clans' elders, the northern former British portion of the country declared its independence as the Republic of Somaliland in May 1991. Although de facto independent and relatively stable compared to the tumultuous south, it was not recognised by any foreign government, until Israel recognised it in 2025.
==== Nazca plate ==== Juan Fernández hotspot (16) 33°54′S 81°48′W, w= 1 az= 084° ±3° rate= 80 ±20 mm/yr San Felix hotspot (36) 26°24′S 80°06′W, w= 0.3 az= 083° ±8° Easter hotspot (7) 26°24′S 106°30′W, w= 1 az= 087° ±3° rate= 95 ±5 mm/yr Galápagos hotspot (10) 0°24′S 91°36′W Nazca Plate, w= 1 az= 096° ±5° rate= 55 ±8 mm/yr Cocos Plate, w= 0.5 az= 045° ±6° Possibly related to the Caribbean large igneous province (main events: 95–88 Ma).
Sources: en.wikipedia.org
H1299, also known as NCI-H1299 or CRL-5803, is a human non-small cell lung carcinoma cell line derived from the lymph node, which is widely used in research. As with other immortalized cell lines, H1299 cells can divide indefinitely. These cells have a homozygous partial deletion of the TP53 gene and as a result, do not express the tumor suppressor p53 protein which in part accounts for their proliferative propensity. These cells have also been reported to secrete the peptide hormone neuromedin B (NMB), but not gastrin-releasing peptide (GRP).
The group released one album in 1965 and three albums in 1966. Dino, Desi & Billy albums contained primarily versions of Top 40 songs made popular by others, with new content being minor. The three boys made an appearance in the Dean Martin film Murderers' Row and sang the Boyce & Hart song, "If You're Thinkin' What I'm Thinkin'". From 1966 to 1970, the group continued to release singles, encountering marginal success, which was not altered by a change of label to Columbia Records in 1969. Also in 1969, the group contributed three songs to the soundtrack of the surf film Follow Me. The group received top billing on the soundtrack album, despite the fact that most of the album featured music by composer Stu Phillips. Later in 1969 the group broke up, due in part to Desi joining his mother's television show and Hinsche wishing to commence university studies. The group was never a favorite of the critics. Writing for AllMusic, music critic Richie Unterberger characterized them as a group that "never had an ounce of credibility", with music that was "innocuously bland in the extreme." These sentiments may be contrasted with the fact that the band was well thought of by the Beach Boys, to the extent that Brian Wilson and Hinsche co-wrote one of the band's original songs, and their final single, "Lady Love". That single was released by Reprise Records in 1970, after the group had broken up. Hinsche's sister, Annie, married Carl Wilson and Hinsche himself worked with the Beach Boys as a backing musician for many years.
In addition to being multi-varied and extraordinarily intense, these new dyes were notoriously unstable, rapidly fading and turning when exposed to sunlight, washing, and other chemical or physical agents. This led to new systems of categorization and study of colorants, which in turn lead to the synthesis of more color-fast modern colorants. Synthetic colors found themselves in not only dyes and paints but also inks and foodstuffs, permeating consumer culture.
To the end of his life, Adorno never abandoned the hope of completing Berg's unfinished opera Lulu. At this time, Adorno was in intense correspondence with Walter Benjamin about the latter's Arcades Project. After receiving an invitation from Horkheimer to visit the Institute in New York, Adorno sailed for New York on 9 June 1937 and stayed for two weeks. While he was in New York, Horkheimer's essays "The Latest Attack on Metaphysics" and "Traditional and Critical Theory," which would soon become instructive for the institute's self-understanding, were the subject of intense discussion. Soon after his return to Europe, Gretel moved to Britain, where she and Adorno were married on 8 September 1937. A little over a month later, Horkheimer telegrammed from New York with news of a position Adorno could take with the Princeton Radio Project, then under the directorship of the Austrian sociologist Paul Lazarsfeld. Yet Adorno's work continued with studies of Beethoven and Richard Wagner (published in 1939 as "Fragments on Wagner"), drafts of which he read to Benjamin during their final meeting, in December on the Italian Riviera. According to Benjamin, these drafts were astonishing for "the precision of their materialist deciphering" as well as the way in which "musical facts ... had been made socially transparent in a way that was completely new to me." In his Wagner study, the thesis later to characterize Dialectic of Enlightenment—man's domination of nature—first emerges. Adorno sailed for New York on 16 February 1938.
Sources: en.wikipedia.org
In science and technology, an arbitrary unit (abbreviated arb. unit, see below) or procedure defined unit (p.d.u.) is a relative unit of measurement to show the ratio of amount of substance, intensity, or other quantities, to a predetermined reference measurement. The reference measurement is typically defined by the local laboratories or dependent on individual measurement apparatus. It is therefore impossible to compare "1 arb. unit" by one measurer and "1000 arb. unit" by another measurer without detailed prior knowledge on how the respective "arbitrary units" were defined; thus, the unit is sometimes called an unknown unit. The unit only serves to compare multiple measurements performed in similar environment, since the ratio between the measurement and the reference is a consistent and dimensionless quantity independent of what actual units are used. Units of such kind are commonly used in fields such as physiology to indicate substance concentration, and spectroscopy to express spectral intensity. When the reference measurement is precisely defined and internationally agreed upon, arbitrary units can also be a unit capable of public comparison. One example of a publicly defined arbitrary unit is the WHO International Unit.
There are three main fermentation methods, warm, cool, and wild or spontaneous. Fermentation may take place in open or closed vessels. There may be a secondary fermentation which can take place in the brewery, in the cask or in the bottle. Brewing yeasts have traditionally been described as "top-fermenting" or "bottom-fermenting", and may be "top-cropped" or "bottom-cropped" according to where the yeast is collected from the fermentation vessel to be reused for the next brew. The yeasts classed as top-fermenting are generally used in warm fermentations, where they ferment quickly, and the yeasts classed as bottom-fermenting are used in cooler fermentations where they ferment more slowly. This terminology is somewhat inappropriate in the modern era; after the widespread application of brewing mycology it was discovered that the two separate collecting methods involved two different yeast species that favoured different temperature regimes, namely Saccharomyces cerevisiae in top-cropping at warmer temperatures and Saccharomyces pastorianus in bottom-cropping at cooler temperatures. As brewing methods changed in the 20th century, cylindro-conical fermenting vessels became the norm and the collection of yeast for both Saccharomyces species is done from the bottom of the fermenter. Thus the method of collection no longer implies a species association. There are a few remaining breweries who collect yeast by top-cropping, such as Samuel Smith's in Yorkshire using Yorkshire Squares, and several German hefeweizen producers.
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in approximately 100 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries. Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2024, it conducted more than 5,930 clinical trials involving over 1 million subjects, as well as over 500 studies for medical device companies. The company is one of the largest participants in the international primate trade and is engaged in animal testing, most specifically animal testing on non-human primates. The company traces its roots to Environmental Sciences Corporation, formed in 1968. It was known as Hazleton from 1972 to 1990, Corning Lab Services from 1990 to 1996, Covance from 1996 to 2021, and Labcorp Drug Development from 2021 to 2023. The company is ranked 992nd on the Fortune 1000 (76th in the healthcare sector).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.